Summary of Key Points
Eligibility criteria for lung cancer screening increasingly need to consider family history of lung cancer, as well as age and smoking status.
Lung cancer screening will reveal a multitude of incidental findings, of variable clinical significance, and with a need for clear pathways of management.
Pulmonary nodule sampling is enhanced by intra‐procedural imaging and cutting‐edge robotic technology.
Systematic thoracic lymph node sampling has implications for treatment efficacy.
Bronchoscopic ablative techniques are feasible for peripheral lung cancers.
Bronchoscopic sampling continues to have a high yield for lung cancer molecular characterization.
Immunotherapy indications have expanded to include early stage and resectable lung cancer.